New drug LM-108 shows promise in early trial for Hard-to-Treat cancers
Disease control
Ongoing
This study is testing an experimental drug called LM-108, given alone or with other cancer treatments, in about 392 people with advanced solid tumors that have not responded to standard therapies. The main goals are to check the drug's safety and find the right dose, and to see i…
Phase: PHASE1, PHASE2 • Sponsor: LaNova Medicines Limited • Aim: Disease control
Last updated May 17, 2026 03:00 UTC